Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
- Conditions
- Liver CirrhosisVirusesHepatitis, Viral, HumanHepatitis C InfectionHepatocellular Carcinoma
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT01804829
- Locations
- 🇺🇸
University of Southern California / Keck Hospital, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: BT062 , intravenous administration
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 64
- Registration Number
- NCT01638936
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation
- Conditions
- Hepatitis B Virus Associated Liver Disease
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT01421212
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 35
- Registration Number
- NCT01001442
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Registration Number
- NCT00800787
- Prev
- 1
- 2
- Next